Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532890 · ClinicalTrials.gov registry record
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
A clinical trial of Graft Rejection and Cardiac Failure, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- 150
- Enrollment target
- 7
- Study locations
NCT06532890: Recruiting study of Graft Rejection and Cardiac Failure, sponsored by Inova Health Care Services.
NCT06532890 is a study of Graft Rejection and Cardiac Failure that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 150 participants, below the 458-participant average among 5 other Graft Rejection trials with a reported enrollment target (67% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06532890, a study of Graft Rejection and Cardiac Failure, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Primary Outcome
A time-to-event analysis will be performed to identify specific circulating microRNAs (miRs) that predict the risk of infection in heart transplant recipients. Infections are defined as any bacterial, viral, fungal, or opportunistic infection leading to: 1) hospitalization, 2) prescription of antimicrobial therapy, or 3) reduction in immunosuppression.
Conditions Studied
Study Locations (7)
Colorado
- Children's Hospital Colorado - Aurora
Michigan
- University of Michigan - Ann Arbor
New York
- Columbia University - New York
Pennsylvania
- University of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University - Nashville
Texas
- Texas Children's Hospital - Houston
Virginia
- Inova Health System - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2029-10-01 |
What NCT06532890 shows while recruiting
NCT06532890 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 458-participant average among 5 other Graft Rejection trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Graft Rejection appearing as the primary indexed condition, and to 0 interventions.
NCT06532890 lists 7 locations in 7 states (Colorado, Michigan, New York).
Frequently Asked Questions
What is clinical trial NCT06532890 about?
NCT06532890 is a clinical study titled "Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs". This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding R...
What is the current status of trial NCT06532890?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-02-06. Estimated completion is 2029-10-01.
What conditions does trial NCT06532890 study?
This clinical trial studies the following conditions: Graft Rejection, Cardiac Failure.
Who is sponsoring clinical trial NCT06532890?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532890 being conducted?
This trial has 7 study locations across Colorado, Michigan, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
RECRUITING
-
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
RECRUITING
-
Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
COMPLETED
-
HLA-Identical Sibling Renal Transplant Tolerance
COMPLETED · NA
-
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI